NeuSpera Medical Announces Milton M. Morris, Ph.D. To Join As Company's CEO

SANTA CLARA, Calif., Aug. 17, 2015 /PRNewswire/ -- NeuSpera Medical Inc. (Priv), a neuromodulation startup company, today announced that Milton M. Morris, Ph.D., M.B.A. has joined as the company's new Chief Executive Officer.

Dr. Morris, who is already a member of the NeuSpera Board of Directors, will begin his tenure by focusing on the company's Series A fundraising activity.

Dr. Morris was recently Sr. Vice President of Research & Development at Cyberonics, Inc. where he had responsibilities for Research, Product Development, Advanced Manufacturing Engineering, Program Management and Emerging Therapies.  During his 6-year tenure, the company received regulatory approvals for 3 implantable neuromodulation devices and a 4th wearable device that provides remote monitoring of patients with epilepsy.  One of these new products contains a fundamental advancement to the company's core therapy Closed-Loop Vagus Nerve Stimulation Therapy for epilepsy while two others enable the company to enter into two large markets Heart Failure and Mobile Health.

Dr. Morris joined Cyberonics from InnerPulse Corporation, a medical device startup company in the Research Triangle Park of North Carolina, where he served as Director of Program Management and Operations. Prior to InnerPulse, Dr. Morris was employed by Guidant Corporation and its successor, Boston Scientific Corporation.  During his 11-year tenure, he held several positions, including Director of Marketing where he served as the $1.6B Arrhythmia Franchise Leader with responsibilities for both the implantable pacemaker and defibrillator businesses for the Cardiac Rhythm Management division. 

"We are delighted to welcome Milton as NeuSpera's President and CEO," said Bing Yeh, Chairman of NeuSpera Medical. "Bringing with him over 23 years of rich experience in the medical device industry, Milton is a dynamic leader and a talented executive with a proven track record of driving technology innovation and business growth. For the past several months, Milton has been working with the company as a consultant.  Under his guidance, the team has made great progress and is now ready to take the next step in addressing the milestones targeted for Series A financing. I am confident that Milton has the leadership qualities and industry experience to propel NeuSpera forward."

"I am excited to be leading NeuSpera Medical a young, fast-moving company with a truly innovative technology," said Dr. Morris.  "It is a privilege to be in a position to positively impact human lives through medical technology a privilege that I take seriously.  NeuSpera has the opportunity to fundamentally change the way neuromodulation therapy is delivered.  I look forward to realizing its great potential."

Dr. Morris holds a Master's in Business Administration from the Kellogg School of Management and a Ph.D. in Electrical Engineering from the University of Michigan.

About NeuSpera

NeuSpera Medical Incorporated (formerly Vivonda Medical Incorporated) is a medical device startup headquartered in Santa Clara, CA that leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies sometimes referred to as electroceuticals.  NeuSpera's implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication, and post-surgical pain.  NeuSpera Medical is committed to bringing forward implantable medical device technology that will improve lives of patients battling with chronic illness.  NeuSpera Medical is currently angel funded with over $1M in capital raised to date.

Investor Relations: www.NeuSpera.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neuspera-medical-announces-milton-m-morris-phd-to-join-as-companys-ceo-300129192.html

SOURCE NeuSpera Medical Incorporated

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.